ASH 2022 Conference Coverage
Playback speed
10 seconds
ASH 2022 ECOG-ACRIN-E1910 Randomized Phase III NCTN Trial: Blinatumomab for Newly Diagnosed BCR::ABL-Negative B-Lineage Adult ALL
By
ASH 2022 Conference Coverage
FEATURING
Mark Litzow
By
ASH 2022 Conference Coverage
FEATURING
Mark Litzow
98 views
December 19, 2022
Login to view comments.
Click here to Login
Leukemia